Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study
Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
The aim of the current study is to evaluate the effectiveness and safety of bempedoic acid combined with ezetimibe and either atorvastatin or rosuvastatin (hereafter defined as triple therapy) in a real-world clinical setting. No drug will be administered during this observational study.
The primary objective of the study is to evaluate the effectiveness of the triple therapy in terms of LDL-C reduction at 8 weeks.
The secondary objectives will include the following:
Key Inclusion Criteria:
Written informed consent to participate
At least 18 years of age
High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment
Patients treated with:
6) Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.
8) No contraindications exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) Life expectancy > 1 -year
Key Exclusion Criteria:
CTRinfo_us@daiichisankyo.com9089926400
Kepler Universitätsklinikum Gmb+, 4600, Austria
Linz, 4021, Austria
Saint Stefan Bei Graz, 8511, Austria
Salzburg, 5026, Austria
Vienna, 1210, Austria
La Louvrière, 7100, Belgium
Leper, 8900, Belgium
Alsfed, 36304, Germany
Mühldorf A. Inn, 84453, Germany
Stanhsdorf B. Berlin, 14532, Germany
Legnagno, 37045, Italy
Pavi, 27100, Italy
Cantabria, 39300, Spain
Las Palmas de GC, 35010, Spain